2020 ASHP/IDSA/PIDS/SIDP共识指南：万古霉素治疗严重MRSA感染的治疗药物监测

2020-03-19 美国卫生系统药师协会 Am J Health Syst Pharm. 19 March 2020.

万古霉素是经典的糖肽类抗菌药物，是对MRSA感染的一线治疗药物。由于其治疗窗窄，有潜在的肾毒性等问题，万古霉素的治疗药物监测就显得尤为必要。但学术界对于万古霉素治疗药物监测的争议一直存在，尤其是在监测

中文标题：

英文标题：

Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections

发布机构：

美国卫生系统药师协会

发布日期：

2020-03-19

简要介绍：

万古霉素是经典的糖肽类抗菌药物，是对MRSA感染的一线治疗药物。由于其治疗窗窄，有潜在的肾毒性等问题，万古霉素的治疗药物监测就显得尤为必要。但学术界对于万古霉素治疗药物监测的争议一直存在，尤其是在监测靶目标到底选用谷浓度还是AUC/MIC的问题上分歧较大，甚有学者提出：采用谷浓度达标作为靶目标进行监测可能是一个糟糕的终点。近年来，由于临床研究的不断深入，对于万古霉素的治疗药物监测靶目标更加倾向于使用AUC/MIC。2020年3月，美国卫生系统药师协会（ASHP）、美国感染病学学会（IDSA）、儿童感染性疾病学会（PIDS）以及感染性疾病药师学会（SIPD）联合推出了万古霉素治疗严重MRSA感染的治疗药物监测共识指南和综述。该综述更新了最新的循证医学证据，对万古霉素治疗严重MRSA感染对治疗药物监测相关问题提出了推荐意见，兼顾成人与儿科患者，厘清既往争议较大的靶目标、监测采血时间点以及儿科剂量调整等相关问题。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=827641c001885904, title=2020 ASHP/IDSA/PIDS/SIDP共识指南：万古霉素治疗严重MRSA感染的治疗药物监测, enTitle=Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections, guiderFrom=Am J Health Syst Pharm. 19 March 2020., authorId=0, author=, summary=万古霉素是经典的糖肽类抗菌药物，是对MRSA感染的一线治疗药物。由于其治疗窗窄，有潜在的肾毒性等问题，万古霉素的治疗药物监测就显得尤为必要。但学术界对于万古霉素治疗药物监测的争议一直存在，尤其是在监测, cover=https://img.medsci.cn/2020330/1585499939888_2020535.jpg, journalId=0, articlesId=null, associationId=761, associationName=美国卫生系统药师协会, associationIntro=美国卫生系统药师协会（American Society of Health-System Pharmacists）成立于1942年，是国家级的专业协会，在全世界拥有30,000多位成员，代表在医院、卫生保健组织、长期监护部门、家庭保健及其他卫生系统工作的药剂师。ASHP协会宗旨是：药师的使命是提供药学保健，是提供直接的、负责的、与药物有关的医疗，目的是改善病人的生活质量。其期刊被国际著名检索工具书和数据库收录、索引。, copyright=0, guiderPublishedTime=Thu Mar 19 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p><span style="color: #333333;">万古霉素是经典的糖肽类抗菌药物，是对MRSA感染的一线治疗药物。由于其治疗窗窄，有潜</span><span style="color: #333333;">在的肾毒性等问题，万古霉素的治疗药物监测就显得尤为必要。但学术界对于万古霉素治疗药物监测的争议一直存在，尤其是在监测靶目标到底选用谷浓度还是AUC/MIC的问题上分歧较大，甚有学者提出：采用谷浓度达标作为靶目标进行监测可能是一个糟糕的终点。近年来，由于临床研究的不断深入，对于万古霉素的治疗药物监测靶目标更加倾向于使用AUC/MIC。2020年3月，美国卫生系统药师协会（ASHP）、美国感染病学学会（IDSA）、儿童感染性疾病学会（PIDS）以及感染性疾病药师学会（SIPD）联合推出了万古霉素治疗严重MRSA感染的治疗药物监测共识指南和综述。该综述更新了最新的循证医学证据，对万古霉素治疗严重MRSA感染对治疗药物监测相关问题提出了推荐意见，兼顾成人与儿科患者，厘清既往争议较大的靶目标、监测采血时间点以及儿科剂量调整等相关问题。</span></p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=1840, tagName=万古霉素), TagDto(tagId=35749, tagName=MRSA感染)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=846, guiderKeyword=感染, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3689, appHits=163, showAppHits=3, pcHits=1586, showPcHits=3649, likes=1, shares=24, comments=5, approvalStatus=1, publishedTime=Mon Mar 30 00:50:08 CST 2020, publishedTimeString=2020-03-19, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 30 00:39:03 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 11:42:38 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])

下载请点击：

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1055643, encodeId=5bf010556434c, content=画重点符号, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:56 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055642, encodeId=78a3105564293, content=要积分就这么难, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055343, encodeId=46b1105534326, content=学习重点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:11:52 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805143, encodeId=12b28051433d, content=万古霉素tdm置换重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9de1762677, createdName=ms9895146479732492, createdTime=Thu Jul 30 08:11:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383021, encodeId=d12f383021b4, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e15a4900095, createdName=18644f4007m, createdTime=Thu May 21 11:32:39 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
2021-09-28 13f0c37dm61暂无昵称

画重点符号

52 0
[GetPortalCommentsPageByObjectIdResponse(id=1055643, encodeId=5bf010556434c, content=画重点符号, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:56 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055642, encodeId=78a3105564293, content=要积分就这么难, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055343, encodeId=46b1105534326, content=学习重点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:11:52 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805143, encodeId=12b28051433d, content=万古霉素tdm置换重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9de1762677, createdName=ms9895146479732492, createdTime=Thu Jul 30 08:11:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383021, encodeId=d12f383021b4, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e15a4900095, createdName=18644f4007m, createdTime=Thu May 21 11:32:39 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
2021-09-28 13f0c37dm61暂无昵称

要积分就这么难

68 0
[GetPortalCommentsPageByObjectIdResponse(id=1055643, encodeId=5bf010556434c, content=画重点符号, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:56 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055642, encodeId=78a3105564293, content=要积分就这么难, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055343, encodeId=46b1105534326, content=学习重点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:11:52 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805143, encodeId=12b28051433d, content=万古霉素tdm置换重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9de1762677, createdName=ms9895146479732492, createdTime=Thu Jul 30 08:11:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383021, encodeId=d12f383021b4, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e15a4900095, createdName=18644f4007m, createdTime=Thu May 21 11:32:39 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
2021-09-27 13f0c37dm61暂无昵称

学习重点

65 0
[GetPortalCommentsPageByObjectIdResponse(id=1055643, encodeId=5bf010556434c, content=画重点符号, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:56 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055642, encodeId=78a3105564293, content=要积分就这么难, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055343, encodeId=46b1105534326, content=学习重点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:11:52 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805143, encodeId=12b28051433d, content=万古霉素tdm置换重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9de1762677, createdName=ms9895146479732492, createdTime=Thu Jul 30 08:11:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383021, encodeId=d12f383021b4, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e15a4900095, createdName=18644f4007m, createdTime=Thu May 21 11:32:39 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
2020-07-30 ms9895146479732492

万古霉素tdm置换重要

93 0
[GetPortalCommentsPageByObjectIdResponse(id=1055643, encodeId=5bf010556434c, content=画重点符号, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:56 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055642, encodeId=78a3105564293, content=要积分就这么难, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Tue Sep 28 11:38:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055343, encodeId=46b1105534326, content=学习重点, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Mon Sep 27 14:11:52 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805143, encodeId=12b28051433d, content=万古霉素tdm置换重要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9de1762677, createdName=ms9895146479732492, createdTime=Thu Jul 30 08:11:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=383021, encodeId=d12f383021b4, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e15a4900095, createdName=18644f4007m, createdTime=Thu May 21 11:32:39 CST 2020, time=2020-05-21, status=1, ipAttribution=)]
2020-05-21 18644f4007m

好文

98 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染指南

2020 ASHP/IDSA/PIDS/SIDP共识指南：万古霉素治疗严重MRSA感染的治疗药物监测

相关指南

拓展阅读

科室

工具

服务